{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T20:35:51Z","timestamp":1770928551830,"version":"3.50.1"},"reference-count":20,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Acta Clinica Belgica"],"published-print":{"date-parts":[[2017,11,2]]},"DOI":"10.1080\/17843286.2017.1316005","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T03:29:20Z","timestamp":1492572560000},"page":"461-464","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Neuroendocrine tumor of cecum in patient treated with imatinib mesylate for blastic phase of chronic myeloid leukemia"],"prefix":"10.1080","volume":"72","author":[{"given":"Sabina","family":"Novakovi\u0107","sequence":"first","affiliation":[{"name":"Community Health Center Zagreb-Center, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anamarija","family":"Kova\u010d Pei\u0107","sequence":"additional","affiliation":[{"name":",","place":["Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hrvoje","family":"Holik","sequence":"additional","affiliation":[{"name":",","place":["Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo\u017eena","family":"Coha","sequence":"additional","affiliation":[{"name":",","place":["Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq201"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402577"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr060"},{"key":"e_1_3_1_6_1","doi-asserted-by":"crossref","unstructured":"Deininger M O\u2019Brien SG Guilhot F Goldman JM Hochhaus A Hughes TP. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. In: ASH Annual Meeting Abstracts; New Orleans (LA). 2009. p. 1126.","DOI":"10.1182\/blood.V114.22.1126.1126"},{"issue":"5","key":"e_1_3_1_7_1","first-page":"933","article-title":"Approval summary for imatinibmesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen MH","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A. Approval summary for imatinibmesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8(5):933\u201342.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S5775"},{"key":"e_1_3_1_9_1","first-page":"2212","article-title":"Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression","volume":"61","author":"Pihan GA","year":"2001","unstructured":"Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res. 2001;61:2212\u20139.","journal-title":"Cancer Res"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-362889"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404025"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403874"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2011_03_256"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-013-0328-2"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"issue":"2","key":"e_1_3_1_17_1","first-page":"1049","article-title":"Neuroendocrine tumors and second primary malignancy\u2013a relationship with clinical impact?","volume":"24","author":"Promegger R","year":"2004","unstructured":"Promegger R, Ensinger C. Neuroendocrine tumors and second primary malignancy\u2013a relationship with clinical impact? Anticancer R. 2004;24(2):1049\u201351.","journal-title":"Anticancer R"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9098(200012)75:4<306::AID-JSO14>3.0.CO;2-3"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403861"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-144790"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2015.12.018"}],"container-title":["Acta Clinica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17843286.2017.1316005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T19:50:14Z","timestamp":1770925814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17843286.2017.1316005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11,2]]}},"alternative-id":["10.1080\/17843286.2017.1316005"],"URL":"https:\/\/doi.org\/10.1080\/17843286.2017.1316005","relation":{},"ISSN":["1784-3286","2295-3337"],"issn-type":[{"value":"1784-3286","type":"print"},{"value":"2295-3337","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yacb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yacb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}